COVID-19 vaccine AZD1222 clinical trials resumed in the UKhttps://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/covid-19-vaccine-azd1222-clinical-trials-resumed-in-the-uk.htmlClinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.
On 6 September, the standard review process triggered a voluntary pause to vaccination across all global trials to allow review of safety data by independent committees, and international regulators. The UK committee has concluded its investigations and recommended to the MHRA that trials in the UK are safe to resume.
The back story to this is that a person being tested developed an unexplained infection, triggering the MHRA investigation. Authorization to resume means it was determined that the infection was not caused by the AstraZeneca vaccine.
